Linagliptin (Tradjenta)

DDP-4 Inhibitor for type II diabetes.

Indicated as an adjunct to diet and exercise to improve control of blood sugar and adults with type II DM.

Should not be used for patients with type I diabetes or for the treatment of diabetic ketoacidosis.

Has not been studied in in combination with insulin therapy.

No dose adjustments needed for hepatic or renal impairment.

Leave a Reply

Your email address will not be published. Required fields are marked *